WallStSmart

Insmed Inc (INSM)vsProQR Therapeutics BV (PRQR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 3610% more annual revenue ($606.42M vs $16.35M). INSM leads profitability with a -2.1% profit margin vs -2.6%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

PRQR

Avoid

24

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -2.81

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

PRQR2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

PRQR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$163.31M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-61.2%2/10

ROE of -61.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : PRQR

The strongest argument for PRQR centers on Debt/Equity, Price/Book.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : PRQR

The primary concerns for PRQR are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

PRQR is growing revenue faster at 6.1% — sustainability is the question.

PRQR generates stronger free cash flow (-14M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

ProQR Therapeutics BV

HEALTHCARE · BIOTECHNOLOGY · USA

ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. The company is headquartered in Leiden, the Netherlands.

Want to dig deeper into these stocks?